Streda, 21. Apríla 2021, 06:55
Cafte vakcina Made in China:
Phase-three trials of China’s CoronaVac vaccine, which were conducted on health-care workers in Brazil, yielded an efficacy rate of just 50.7%.
This is barely above the 50% threshold set by the World Health Organisation for covid-19 vaccines.
The results of a real-world trial were even worse: the vaccine was estimated to be just 49.6% effective against symptomatic covid-19 cases, or 35.1% effective against asymptomatic infections.
Effective or not, Sinovac Biotech, the jab developer, has already exported doses to 19 different countries. In China, nearly 180m people have already been vaccinated.
Read why it is significant that the trial was held in Brazil, and why the vaccine is still useful
-
Prílohy
-

- 176232027_10159557617219060_5361256583560041068_n.png (91.24 KiB) 673 zobrazení
"Auto je napisane na mna, ale inak s nim nic nemam!"
-- P.R.